Health
Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test – News-Medical.net
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expan…
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.
Avacta, in partnership with Cytiva, is developing a rapid test strip for use with patient saliva that aims to provide a result in a few minutes, indicating whether the patient is currently infected with the S…
-
Noosa News24 hours agoHow Lily Steele-Park took her rapist to court and won
-
General23 hours agoBrick portico a relic of ‘prestigious’ Horton College in northern midlands
-
Business17 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today
-
Noosa News20 hours agoQueenslanders to continue legal challenges against COVID-19 directives after successful appeal